Effects of Mindfulness-Based Stress Reduction on Depression, Anxiety, and Pain in Patients With Postherpetic Neuralgia

Zhu, Xiaoqin; Hu, Ping; Fan, Zhengying; Zhan, Wenxian; Wang, Huijuan; Yang, Yang; Zhou, Zubin; Ma, Lan; Gao, Haiyan

doi:10.1097/nmd.0000000000000998

Cited by 18 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 52 , 64–66 There were 3 (9%) studies each for multiple NeuP conditions 31 , 44 , 48 and for postherpetic neuralgia. 53 , 56 , 61 Two (6%) studies were for painful peripheral neuropathy in HIV. 42 , 67 One (3%) study examined individuals with multiple sclerosis and peripheral neuropathy, 58 and another study was on NeuP in cancer survivors (3%).…”

Section: Resultsmentioning

confidence: 99%

Psychologically based interventions for adults with chronic neuropathic pain: a scoping review

Oguchi,

Nicholas,

Asghari

et al. 2024

Pain Medicine

View full text Add to dashboard Cite

Objective As psychologically-based interventions have been shown to have clinical utility for adults with chronic pain generally, a similar benefit might be expected in the management of chronic neuropathic pain (NeuP). However, to date this has not been established, with existing systematic reviews on this topic being hampered by the scarcity of Randomised Controlled Trials (RCTs). This review aimed to identify the type of psychologically-based interventions studied for adults with chronic NeuP. It also aimed to assess whether there are enough RCTs to justify undertaking an updated systematic review. Methods Seven databases and two clinical trial registries were searched for NeuP and psychologically-based interventions from database inception to December 2021, and the search was updated in February 2023. The search was broadened by reviewing the reference list of included studies and contacting field experts. Predetermined study characteristics were extracted. Results Of 4682 records screened, 33 (less than 1%) articles met the eligibility criteria. Four broad intervention approaches were observed, including cognitive-behavioural approaches (n = 16), mindfulness/meditation (n = 10), trauma focused therapy (n = 4), and hypnosis (n = 3). Thirteen RCTs were identified, and of these, nine retained 20 participants in each arm at post-treatment. Conclusions Cognitive Behavioural Therapy was the most common therapeutic approach identified, whereas mindfulness/meditation was the most frequently used technique. Almost half to two-thirds of the studies reported significant improvements in either pain, disability, or distress, suggesting psychologically-based interventions are potentially beneficial for adults with chronic NeuP. An updated systematic review seems warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Psychologically based interventions for adults with chronic neuropathic pain: a scoping review

Oguchi,

Nicholas,

Asghari

et al. 2024

Pain Medicine

View full text Add to dashboard Cite

show abstract

“…reduce the quality of life of the patients [1, 2] and severely impact their personal and social functions [3].…”

Section: Discussionmentioning

confidence: 99%

Intravenous Patient-Controlled Analgesia with Esketamine Improves Early Depressive Symptoms in Patients with Postherpetic Neuralgia: A Single-Center Retrospective Cohort Study

Qiu,

Chen,

Jia

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective Patients with Postherpetic Neuralgia (PHN) often exhibit depressive-like symptoms, significantly impacting their quality of life. Esketamine, known for its analgesic properties, has also been recognized for its rapid antidepressant effects. However, its efficacy in the treatment of PHN requires further exploration. This study aims to evaluate the impact of intravenous patient-controlled analgesia with esketamine on depressive mood in PHN patients. Methods This retrospective study analyzed PHN patients hospitalized and treated at the affiliated hospital of Southwest Medical University from June 2021 to March 2023. Patients were divided into the esketamine group (E group) and the sufentanil group (S group) based on their treatment regimens. Primary outcomes included pain NRS, depression PHQ-9, and anxiety GAD-7 scores measured before treatment, and at 3 days, 7 days, 1 month, 2 months, and 3 months post-treatment. Results A total of 83 patients were included in the analysis. Before treatment, there were no statistically significant differences in pain NRS, depression PHQ-9, and anxiety GAD-7 scores between the two groups (P > 0.05). Compared to before treatment, significant reductions in pain NRS scores were observed at all post-treatment time points in both groups (P < 0.05), with no differences between groups (P > 0.05). The E group exhibited significantly lower depression PHQ-9 scores than the S group at 3 days and 7 days post-treatment (P < 0.05), but no significant differences were observed at 1 month, 2 months, and 3 months (P > 0.05). Anxiety GAD-7 scores were significantly lower in the E group compared to the S group at 3 days, 7 days, and 3 months post-treatment (P < 0.05), with no statistical differences at 1 month or 2 months post-treatment (P > 0.05). Conclusion Intravenous patient-controlled analgesia with esketamine not only alleviates pain in PHN patients but also improves early symptoms of anxiety and depression.

show abstract

“…There is also developing evidence for the efficacy of behavioral interventions in management of post-viral pain. 53 A recent trial comparing pregabalin alone and pregabalin+cognitive behavioral therapy (CBT) for management of PHN showed improvement in neuropathic symptoms of burning and allodynia as well as pain-related catastrophizing in the CBT group. Moreover, those who completed CBT while taking pregabalin showed downregulation of mRNA expression of IL-6.…”

Section: Post-viral Painmentioning

confidence: 99%

Post-Viral Pain, Fatigue, and Sleep Disturbance Syndromes: Current Knowledge and Future Directions

Tackey,

Slepian,

Clarke

et al. 2023

Canadian Journal of Pain

View full text Add to dashboard Cite

Background Post-viral pain syndrome, also known as post-viral syndrome, is a complex condition characterized by persistent pain, fatigue, musculoskeletal pain, neuropathic pain, neurocognitive difficulties, and sleep disturbances that can occur after an individual has recovered from a viral infection. Aims This narrative review provides a summary of the sequelae of post-viral syndromes, viral agents that cause it, and the pathophysiology, treatment, and future considerations for research and targeted therapies. Methods Medline, PubMed, and Embase databases were used to search for studies on viruses associated with post-viral syndrome. Conclusion Much remains unknown regarding the pathophysiology of post-viral syndromes, and few studies have provided a comprehensive summary of the condition, agents that cause it, and successful treatment modalities. With the COVID-19 pandemic continuing to affect millions of people worldwide, the need for an understanding of the etiology of post-viral illness and how to help individuals cope with the sequalae is paramount.

show abstract

Effects of Mindfulness-Based Stress Reduction on Depression, Anxiety, and Pain in Patients With Postherpetic Neuralgia

Cited by 18 publications

References 23 publications

Psychologically based interventions for adults with chronic neuropathic pain: a scoping review

Psychologically based interventions for adults with chronic neuropathic pain: a scoping review

Intravenous Patient-Controlled Analgesia with Esketamine Improves Early Depressive Symptoms in Patients with Postherpetic Neuralgia: A Single-Center Retrospective Cohort Study

Post-Viral Pain, Fatigue, and Sleep Disturbance Syndromes: Current Knowledge and Future Directions

Contact Info

Product

Resources

About